Efficient downregulation of VEGF in Retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2613-2627

  Chen, Cheng Wei ^a   Yeh, Ming Kung ^b   Shiau, Chia Yang ^c   Chiang, Chiao Hsi ^d   Lu, Da Wen ^e  

^a Chengwei Biotechnology Co Ltd   (Taiwan)

^b Military of National Defense Medical Affairs Bureau   (Taiwan)

^c Graduate Institute of Medical Sciences   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Liposome; Retinal pigment epithelial cells; siRNA delivery; Vascular endothelial growth factor

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; INTEGRIN; LIPOSOME; MACROGOL; SMALL INTERFERING RNA; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; HUMAN; HUMAN CELL; HYDRATION; PARTICLE SIZE; PIGMENT CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE CHARGE; ZETA POTENTIAL;

LIPOSOME; RETINAL PIGMENT EPITHELIAL CELLS; SIRNA DELIVERY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

CELL LINE; CELL SURVIVAL; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; INTEGRINS; INTRACELLULAR SPACE; LIPOSOMES; MICROSCOPY, CONFOCAL; PARTICLE SIZE; PROTEIN ISOFORMS; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880631788     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39622     Document Type: Article

References (43)

1. Zabner J. Cationic lipids used in gene transfer. Adv Drug Deliv Rev. 1997;27(1):17-28.
2. Liu F, Huang L. Development of non-viral vectors for systemic gene delivery. J Control Release. 2002;78(1-3):259-266.
3. Dass CR, Choong PF. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release. 2006;113(2):155-163.
4. Gao Y, XL Liu, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine. 2011;6(1):1017-1025.
5. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-25):3477-3496.
6. He L, Yang L, Duan Y, et al. Cytotoxicity and hemocompatibility of a family of novel MeO-PEG-poly (D,L-lactic-co-glycolic acid)-PEG-OMe triblock copolymer nanoparticles. J Appl Polym Sci. 2009; 113(5):2933-2944.
7. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992;52(12):3255-3261.
8. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10(2): 103-117.
9. Zhang P, Wang Y, Hui Y, et al. Inhibition of VEGF expression by targeting HIF-1 alpha with small interference RNA in human RPE cells. Ophthalmologica. 2007;221(6):411-417.
10. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49(10):4523-4527.
11. Mackenzie F, Ruhrberg C. Diverse roles for VEGF-A in the nervous system. Development. 2012;139(8):1371-1380.
12. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One. 2008;3(11):e3554.
13. Avci B, Avci R, Inan UU, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci. 2009;50(7):3438-3446.
14. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426-433.
15. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61(10):850-862.
16. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005; 167(5):1451-1459.
17. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331-371.
18. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16(5):645-659.
19. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155(2):421-428.
20. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-138.
21. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93(18):9764-9769.
22. Anderson DH, Johnson LV, Hageman GS. Vitronectin receptor expression and distribution at the photoreceptor-retinal pigment epithelial interface. J Comp Neurol. 1995;360(1):1-16.
23. Lin H, Clegg DO. Integrin alphavbeta5 participates in the binding of photoreceptor rod outer segments during phagocytosis by cultured human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1998; 39(9):1703-1712.
24. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673-687.
25. Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ. Cell adhesion molecules for targeted drug delivery. J Pharm Sci. 2006;95(9):1856-1872.
26. Chen CW, Lu DW, Yeh MK, Shiau CY, Chiang CH. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine. 2011;6: 2567-2580.
27. Meure LA, Foster NR, Dehghani F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech. 2008;9(3):798-809.
28. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine. 2008; 26(18):2225-2233.
29. Tiwari S, Goyal AK, Mishra N, et al. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine. J Control Release. 2009;140(2):157-165.
30. Ye Y, De Leon J, Yokoyama N, Naidu Y, Camerini D. DBR1 siRNA inhibition of HIV-1 replication. Retrovirology. 2005;2:63.
31. Hu CS, Chiang CH, Hong PD, Yeh MK. Influence of charge on FITC-BSA-loaded chondroitin sulfate-chitosan nanoparticles upon cell uptake in human Caco-2 cell monolayers. Int J Nanomedicine. 2012;7: 4861-4872.
32. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release. 2011;153(2):141-148.
33. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther. 2010;18(4):828-834.
34. Zhang Y, Li H, Sun J, et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm. 2010;390(2):198-207.
35. Sakai H, Tomiyama KI, Sou K, Takeoka S, Tsuchida E. Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin-vesicles as oxygen carriers in a liquid state. Bioconjug Chem. 2000;11(3):425-432.
36. Pinkse GG, Bouwman WP, Jiawan-Lalai R, Terpstra OT, Bruijn JA, de Heer E. Integrin signaling via RGD peptides and anti-beta1 antibodies confers resistance to apoptosis in islets of Langerhans. Diabetes. 2006; 55(2):312-317.
37. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443-453.
38. Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J Control Release. 2011;156(2):203-211.
39. Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry. 1998;37(37):12875-12883.
40. Simoes S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005;2(2):237-254.
41. Dan N. Effect of liposome charge and PEG polymer layer thickness on cell-liposome electrostatic interactions. Biochim Biophys Acta. 2002; 1564(2):343-348.
42. Jung SH, Seong H, Cho SH, Jeong KS, Shin BC. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm. 2009;382(1-2):254-261.
43. Chen Z, Chen CZ, Gong WR, Li JP, Xing YQ. Integrin-alpha5 mediates epidermal growth factor-induced retinal pigment epithelial cell proliferation and migration. Pathobiology. 2010;77(2):88-95.